Skip to main content

Annual AFP Conference 2022

Some of our AFP trainees presented their research at the annual conference in Bristol

Several of our Academic Foundation Programme (AFP) trainees attended the annual AFP conference in Bristol in June 2022.  They were excellent ambassadors for our programme showcasing a range of different projects, which reflect their hard work and passion for research.

Special congratulations go to Dr Emma Farrington who won the Covid19 section prize, presenting her findings from an in-depth examination of how Foundation doctors experienced death through the pandemic.

Emma Farrington, F2

Emma has been exploring foundation doctors’ experiences of patient death during the coronavirus pandemic.

She interviewed 17 doctors about the challenges and rewards of providing end-of-life care at such a unique time. Analysing their responses has emphasised the impact on both the person and the professional, and the crucial role for support.

emma-farrington-afp

Anna Harvey, F1

Anna's work focuses on the continuing impact of being a widening access to medicine student throughout medical school and into a career as a doctor.

Her AFP year one project uses interpretative phenomenological analysis to build rich narratives of the experiences of students from widening access backgrounds during their first year at medical school. The ultimate aim is to use this research to develop interventions that can be put in place by universities to ensure all students are able to achieve their full potential.

anna-harvey

Jessica Katanga, F1

Jessica gave an oral presentation on her work looking at the link between cognitive impairment and hearing impairment.

Jessica used data from the national brain bank dedicated to Dementia research to see which theories are best supported. 

jessica-katanga-afp

Sarah Rae, F1

Sarah’s project in medical oncology has focussed on looking at patients presenting to Newcastle ECMC who have had genomic profiling completed of their tumours.

Sarah compared this to The Cancer Genome Atlas data for common tumour types and looked at how we use this information to match patients with advanced cancer to Phase I clinical trials.

sarah-rae-afp